Bull Case

Commercial adoption accelerates in the lead indication and adjacent uses, lifting revenue growth above smaller peers that remain concentrated in narrower specialty niches.

Operating leverage improves as fixed R&D and SG&A are spread over higher sales, allowing margins to expand faster than peers with less scalable cost bases.

Clinical and regulatory milestones land on schedule, reducing financing pressure and supporting broader physician uptake versus peers facing slower evidence generation.

Balance-sheet strain eases through improved cash generation or non-dilutive funding, lowering dilution risk relative to peers that must repeatedly tap capital markets.

Base Case

Revenue grows modestly as ANEB converts a limited set of accounts, while peers with larger commercial footprints still outpace absolute scale.

Gross margin and operating margin remain constrained by small revenue base and ongoing launch costs, keeping profitability below stronger specialty peers.

Clinical progress continues but commercialization remains uneven, so demand improves gradually rather than inflecting sharply versus peers with established reimbursement.

Liquidity stays manageable but leverage and weak interest coverage keep financing optionality tighter than peers with stronger cash flow generation.

Bear Case

Adoption stalls or reverses, causing revenue to undershoot peers and leaving the company unable to absorb fixed operating costs.

Persistent operating losses and negative interest coverage force additional financing, increasing dilution risk versus better-capitalized peers.

Clinical or regulatory setbacks delay expansion into new uses, weakening demand visibility and reducing the company’s ability to compete on evidence.

Tighter capital access or covenant pressure constrains commercialization spending, allowing peers with stronger balance sheets to widen their lead.

Overall Score

ANEB’s forward path is most likely a modest-growth, capital-constrained commercialization case, with upside tied to adoption and evidence generation but downside limited by financing pressure.